Wall Street analyst estimates for ABVC BioPharma, Inc. (ABVC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Valuation Ratios
| Price / Book | 3.18 |
| EV / EBITDA | -7.04 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $6956 | $701719 | $483045 | $355797 | $969783 | $152430 | $509589 | 0 |
| Cost of Revenue | $32 | 0 | $228890 | $20137 | $18716 | $5086 | $286415 | $302037 | $763 | 0 |
| Gross Profit | -$32 | 0 | -$221934 | $681582 | $464329 | $350711 | $683368 | -$149607 | $508826 | 0 |
| Research & Development | $10.0M | $3.2M | $988721 | $1.0M | $549658 | $1.0M | $2.7M | $1.1M | $179272 | $121085 |
| Selling, General & Admin | $997203 | $967085 | $1.6M | $3.1M | $8.4M | $11.1M | $13.1M | $5.6M | $5.0M | $7.0M |
| Operating Expenses | $11.0M | $4.1M | $2.6M | $4.1M | $9.0M | $12.1M | $15.8M | $6.6M | $5.2M | $7.2M |
| Operating Income | -$11.0M | -$4.1M | -$2.8M | -$3.5M | -$8.5M | -$11.7M | -$15.1M | -$6.8M | -$4.7M | -$7.2M |
| EBITDA | -$11.0M | -$4.1M | -$5.9M | -$3.5M | -$10.4M | -$11.0M | -$15.2M | -$6.3M | -$4.3M | -$7.4M |
| Interest Expense | $10170 | $103460 | $462751 | $482014 | $405032 | $227210 | $293968 | $1.3M | $825899 | $415890 |
| Pre-tax Income | -$11.0M | -$4.2M | -$6.4M | -$4.0M | -$10.8M | -$11.2M | -$15.5M | -$8.0M | -$5.4M | -$8.4M |
| Income Tax | $836 | $830 | -$365097 | -$77041 | -$220352 | $825024 | $797778 | $256006 | -$110539 | $24154 |
| Net Income | -$11.0M | -$4.2M | -$5.6M | -$3.6M | -$9.8M | -$12.8M | -$16.4M | -$7.8M | -$4.9M | -$7.9M |
| EPS | $-10.21 | $-3.58 | $-4.69 | $-2.10 | $-5.00 | $-5.10 | $-5.20 | $-1.80 | $-0.42 | $-0.39 |
| EPS (Diluted) | $-10.80 | $-3.58 | $-4.69 | $-2.10 | $-5.00 | $-5.10 | $-5.20 | $-1.80 | $-0.42 | $-0.39 |
| Shares Outstanding (Diluted) | $1.2M | $1.2M | $1.2M | $1.7M | $2.0M | $2.5M | $3.2M | $4.3M | $11.7M | $23.3M |
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks